Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Tg Therapeutics (TGTX) over the last 9 years, with Q3 2025 value amounting to $6.7 million.

  • Tg Therapeutics' Interest Expenses fell 3795.24% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.3 million, marking a year-over-year increase of 3956.88%. This contributed to the annual value of $24.0 million for FY2024, which is 9047.17% up from last year.
  • As of Q3 2025, Tg Therapeutics' Interest Expenses stood at $6.7 million, which was down 3795.24% from $6.7 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Interest Expenses high stood at $10.8 million for Q3 2024, and its period low was $1.0 million during Q3 2021.
  • Over the past 5 years, Tg Therapeutics' median Interest Expenses value was $2.9 million (recorded in 2022), while the average stood at $3.8 million.
  • Examining YoY changes over the last 5 years, Tg Therapeutics' Interest Expenses showed a top increase of 19532.34% in 2025 and a maximum decrease of 3795.24% in 2025.
  • Quarter analysis of 5 years shows Tg Therapeutics' Interest Expenses stood at $1.1 million in 2021, then surged by 165.25% to $2.9 million in 2022, then fell by 15.06% to $2.4 million in 2023, then surged by 190.46% to $7.1 million in 2024, then decreased by 4.82% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q3 2025, $6.7 million for Q2 2025, and $6.8 million during Q1 2025.